# Marks’ Biochemistry: Synthesis of TAG and VLDL and fate of VLDL

Created time: April 4, 2022 11:24 AM

## **Synthesis of Triacylglycerols and VLDL Particles**

In liver and adipose tissue, *triacylglycerols* are produced by a pathway that contains a phosphatidic acid intermediate (Fig. 31.20). Phosphatidic acid is also the precursor of the glycerolipids found in cell membranes and the blood lipoproteins.

**FIGURE 31.20**

![https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/m_lieberman9781496324818-ch031_f020_1602178826.69412.jpeg?Expires=1652066471&Signature=gcFglfW5tyl1XuTDIRfh4JVEaZ2Brod542QX5g8sSwNGf5nZoaSec6sbtDElBi0PrZeEmdU6upOxwNo4JvUJnWoELYMsfGh03ne-7YxLEMwotQxq6O9J0vMnd8iiiscZ~kLRkNmURqfrogeUaPNS~cWn91D3agGJRRaBD7PojTekvw5HU4GUfMep6olfZSBrptFK8XyU5UAie9QuGr6LlRFkZ4zBDXT-it--GUkAiuM0b8z-OHSUo~-~vW1rkHZthWSOF0HV5ftNFY~WVGQo2OPB~ZycmhHJqMKQ8dyDgeNOCA8XvjH4I7wkYC9aEcXVHYTzmNdCPCOl4ngf2BTumA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA](https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/m_lieberman9781496324818-ch031_f020_1602178826.69412.jpeg?Expires=1652066471&Signature=gcFglfW5tyl1XuTDIRfh4JVEaZ2Brod542QX5g8sSwNGf5nZoaSec6sbtDElBi0PrZeEmdU6upOxwNo4JvUJnWoELYMsfGh03ne-7YxLEMwotQxq6O9J0vMnd8iiiscZ~kLRkNmURqfrogeUaPNS~cWn91D3agGJRRaBD7PojTekvw5HU4GUfMep6olfZSBrptFK8XyU5UAie9QuGr6LlRFkZ4zBDXT-it--GUkAiuM0b8z-OHSUo~-~vW1rkHZthWSOF0HV5ftNFY~WVGQo2OPB~ZycmhHJqMKQ8dyDgeNOCA8XvjH4I7wkYC9aEcXVHYTzmNdCPCOl4ngf2BTumA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

[View Original](https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/lieberman9781496324818-ch031_f020_1602178826.69412.jpeg?Expires=1652066471&Signature=BmxD8BuTrbwEY7vJWKw3dH6FYMdgyDK~SAgggrEh~~yvbJJSbQa7wewXgVMA6eI-pKn~Crax6gWgQuP3cxwUuSJ1LZrR24iZLtLZLAmnAqelK8hQ24bzQ3va0Vl2rrjCDRSJ6kD2~7HDfbxX1xzH-WMtEqqs8m8sIr4eP4CxYpXSuwlA5tprpnJaaARlq28ZERXkZIqKjwJNKxLMd2oOQQ5jAbqg0EJfPgNK0~sLoC-OpymiRocqCibxB7Wf2~Pbj351JQqluXSfOyjMrRP2Py6tdk7~3c1E~wXj0tvJgsqdHTWSHww35C62DZqMQkmcXuX8byUnohahG5wN98Zt8w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)[Download Slide (.ppt)](https://meded-lwwhealthlibrary-com.eproxy.lib.hku.hk/downloadimage.aspx?sec=249267811&image=https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/lieberman9781496324818-ch031_f020_1602178826.69412.jpeg?Expires=1652066471&Signature=BmxD8BuTrbwEY7vJWKw3dH6FYMdgyDK~SAgggrEh~~yvbJJSbQa7wewXgVMA6eI-pKn~Crax6gWgQuP3cxwUuSJ1LZrR24iZLtLZLAmnAqelK8hQ24bzQ3va0Vl2rrjCDRSJ6kD2~7HDfbxX1xzH-WMtEqqs8m8sIr4eP4CxYpXSuwlA5tprpnJaaARlq28ZERXkZIqKjwJNKxLMd2oOQQ5jAbqg0EJfPgNK0~sLoC-OpymiRocqCibxB7Wf2~Pbj351JQqluXSfOyjMrRP2Py6tdk7~3c1E~wXj0tvJgsqdHTWSHww35C62DZqMQkmcXuX8byUnohahG5wN98Zt8w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&ChapterSecID=249267688&BookID=2170)

**Synthesis of triacylglycerol in liver and adipose tissue.**

Glycerol 3-phosphate is produced from glucose in both tissues. It is also produced from glycerol in liver, but not in adipose tissue, which lacks glycerol kinase. The steps from glycerol 3-phosphate are the same in the two tissues. *FA*, fatty acyl group; *CoA*, coenzyme A; *ADP*, adenosine diphosphate; *ATP*, adenosine triphosphate; *DHAP*, dihydroxyacetone phosphate; *NAD*, nicotinamide adenine dinucleotide; *VLDL*, very-low-density lipoprotein (VLDL).

The sources of glycerol 3-P, which provides the glycerol moiety for triacylglycerol synthesis, differ in liver and adipose tissue. In liver, glycerol 3-P is produced from the phosphorylation of glycerol by glycerol kinase or from the reduction of dihydroxyacetone phosphate (DHAP) derived from glycolysis. White adipose tissue lacks glycerol kinase and can produce glycerol 3-P only from glucose via DHAP. Thus, adipose tissue can store fatty acids only when glycolysis is activated; that is, in the fed state.

The gene for glycerol kinase is located on the X-chromosome, close to the *DMD* gene (which codes for dystrophin) and the *NROB1* gene, which codes for a protein designated as DAX1. DAX1 is critical for the development of the adrenal glands, pituitary, hypothalamus, and gonads. Complex glycerol kinase deficiency results from a contiguous deletion of the X-chromosome, which deletes all or part of the glycerol kinase gene along with the *NROB1* gene and/or the *DMD* gene. The patient exhibits adrenal insufficiency, hyperglycerolemia, and, if the *DMD* gene is deleted, Duchenne’s muscular dystrophy.

In both adipose tissue and liver, triacylglycerols are produced by a pathway in which glycerol 3-P reacts with fatty acyl-CoA to form phosphatidic acid. Dephosphorylation of phosphatidic acid produces DAG. Another fatty acyl-CoA reacts with the DAG to form a triacylglycerol (see Fig. 31.20).

The triacylglycerol, which is produced in the smooth endoplasmic reticulum of the liver, is packaged with cholesterol, phospholipids, and proteins (synthesized in the rough endoplasmic reticulum) to form VLDL (Fig. 31.21, see [Fig. 29.7](https://meded-lwwhealthlibrary-com.eproxy.lib.hku.hk/content.aspx?legacySectionId=lieberman5-lieberman-5-lieberman-ch029-fig007)). The microsomal triglyceride transfer protein (MTP), which is required for chylomicron assembly, is also required for VLDL assembly. The major protein of VLDL is apolipoprotein B-100 (apoB-100). There is one long apoB-100 molecule wound through the surface of each VLDL particle. ApoB-100 is encoded by the same gene as the apoB-48 of chylomicrons, but it is a longer protein (see [Fig. 29.9](https://meded-lwwhealthlibrary-com.eproxy.lib.hku.hk/content.aspx?legacySectionId=lieberman5-lieberman-5-lieberman-ch029-fig009)). In intestinal cells, RNA editing produces a stop codon in the mRNA produced by the gene and a protein which is 48% the size of apoB-100 (apoB-48; see [Figure 29.9](https://meded-lwwhealthlibrary-com.eproxy.lib.hku.hk/content.aspx?legacySectionId=lieberman5-lieberman-5-lieberman-ch029-fig009)).

**FIGURE 31.21**

![https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/m_lieberman9781496324818-ch031_f021_1602178826.70975.jpeg?Expires=1652066471&Signature=iD5v2G2icH4uXoJjR7FfctEQqZG3bqozouj3XNUqK03blWSe3ZSIqLyW7unKcwFypxHxUhPU9jTwEsKpTtr7IncZLecL0B1Auy1ltvlw4VjXqdOE41jZgMzzJR2hlDx73skMlYGmpO81OZAdzjPWnqzx7m2SINr-RFwgQxUvaJ~0PS4pr2YUfioAQsGfXEaN827EC-rm443SX1JzbyUUwSGfhfaQwiIYQFR6hJlGdhqb9o1O6OfmaxMITrqVA3pCG4Vkv4H1QqfA9eUYv1eKHWlsz3klQRcFqgubjlyHk2W30DaaxtZhlbJg0laUBv9DkANKWrnLSSAb-OfiAf8sOw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA](https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/m_lieberman9781496324818-ch031_f021_1602178826.70975.jpeg?Expires=1652066471&Signature=iD5v2G2icH4uXoJjR7FfctEQqZG3bqozouj3XNUqK03blWSe3ZSIqLyW7unKcwFypxHxUhPU9jTwEsKpTtr7IncZLecL0B1Auy1ltvlw4VjXqdOE41jZgMzzJR2hlDx73skMlYGmpO81OZAdzjPWnqzx7m2SINr-RFwgQxUvaJ~0PS4pr2YUfioAQsGfXEaN827EC-rm443SX1JzbyUUwSGfhfaQwiIYQFR6hJlGdhqb9o1O6OfmaxMITrqVA3pCG4Vkv4H1QqfA9eUYv1eKHWlsz3klQRcFqgubjlyHk2W30DaaxtZhlbJg0laUBv9DkANKWrnLSSAb-OfiAf8sOw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

[View Original](https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/lieberman9781496324818-ch031_f021_1602178826.70975.jpeg?Expires=1652066471&Signature=4oQihnCDDkw3R6FT~CZGSPqSGBJG5gF5ZP~lrPwg4HwzTdshkINiGyNo8IXkr4LG-oWxzJ-4KpcS-NLPogtnBR9eSLhwQ6f3EOk1vcPQ9Cb8bw55wkZaSmGzFntKT~FjACy8wFJnui2o4BBc-3Ys9evLem4yoIO9nUBRhx8~qWNE5LLEPpZC5NvuTYnp7GH~0eQZGJFbHDP8728jbhg6G~-zZQ01uhobAsX8zOv-MqDu6EGDM7IKQMdZ3nSSwib-KfX~7qZNnOHe1wIm2DqkJr-CguxkYCqLFpv5MD-hOx-Zb~G1In1ddD6fbhsR~OXcdkSjMw0hEG1yrw9vXgKoxg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)[Download Slide (.ppt)](https://meded-lwwhealthlibrary-com.eproxy.lib.hku.hk/downloadimage.aspx?sec=249267817&image=https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/lieberman9781496324818-ch031_f021_1602178826.70975.jpeg?Expires=1652066471&Signature=4oQihnCDDkw3R6FT~CZGSPqSGBJG5gF5ZP~lrPwg4HwzTdshkINiGyNo8IXkr4LG-oWxzJ-4KpcS-NLPogtnBR9eSLhwQ6f3EOk1vcPQ9Cb8bw55wkZaSmGzFntKT~FjACy8wFJnui2o4BBc-3Ys9evLem4yoIO9nUBRhx8~qWNE5LLEPpZC5NvuTYnp7GH~0eQZGJFbHDP8728jbhg6G~-zZQ01uhobAsX8zOv-MqDu6EGDM7IKQMdZ3nSSwib-KfX~7qZNnOHe1wIm2DqkJr-CguxkYCqLFpv5MD-hOx-Zb~G1In1ddD6fbhsR~OXcdkSjMw0hEG1yrw9vXgKoxg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&ChapterSecID=249267688&BookID=2170)

**Composition of a typical very-low-density lipoprotein (VLDL) particle.**

The major component is triacylglycerol (TG). *C*, cholesterol; *CE*, cholesterol ester; *PL*, phospholipid.

Abetalipoproteinemia, which is caused by a lack of MTP (see [Chapter 29](https://meded-lwwhealthlibrary-com.eproxy.lib.hku.hk/content.aspx?legacySectionId=lieberman5-lieberman-5-lieberman-ch029)) activity, results in an inability to assemble both chylomicrons in the intestine and VLDL particles in the liver.

VLDL is processed in the Golgi complex and secreted into the blood by the liver (Figs. 31.22 and 31.23). The fatty acid residues of the triacylglycerols ultimately are stored in the triacylglycerols of adipose cells. Note that, in comparison to chylomicrons (see [Chapter 29](https://meded-lwwhealthlibrary-com.eproxy.lib.hku.hk/content.aspx?legacySectionId=lieberman5-lieberman-5-lieberman-ch029)), VLDL particles are more dense, as they contain a lower percentage of triglyceride (and hence more protein) than do the chylomicrons. Similar to chylomicrons, VLDL particles are first synthesized in a nascent form, and on entering the circulation, they acquire apolipoproteins CII and E from HDL particles to become mature VLDL particles.

**FIGURE 31.22**

![https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/m_lieberman9781496324818-ch031_f022_1602178826.741.jpeg?Expires=1652066471&Signature=FifK4tpkhya-zOYpgWGGmENj6q9Yr4VbFtgJjqqaV5c6wulkt4GH8ntYKhOgDqAXsuSNWe0CnTxMf5EAyUlydXQgSOgntKxnRRjtTcsO4e0Y8B57cqLrFgTv2RbJTQI8R5fgMmlepET3BvFDk6qE3k2t0IXn9Tc7WvI4bFaOgETIgtcSR4upxpmYKOD4HxhszRPzTBIRJaJjjQb9iyBuIgFkOwMtMKf7p66jZqME3mb4sYisd7NfxmA7JQHuXb9B-vQWkkRnd1yAx0LLRNCIzVP79~VTv9yiSj617GadMG5N~Wsa5WG0UzeW1Y2YA~lIu42en~3E55TX2ytaEgR-qQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA](https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/m_lieberman9781496324818-ch031_f022_1602178826.741.jpeg?Expires=1652066471&Signature=FifK4tpkhya-zOYpgWGGmENj6q9Yr4VbFtgJjqqaV5c6wulkt4GH8ntYKhOgDqAXsuSNWe0CnTxMf5EAyUlydXQgSOgntKxnRRjtTcsO4e0Y8B57cqLrFgTv2RbJTQI8R5fgMmlepET3BvFDk6qE3k2t0IXn9Tc7WvI4bFaOgETIgtcSR4upxpmYKOD4HxhszRPzTBIRJaJjjQb9iyBuIgFkOwMtMKf7p66jZqME3mb4sYisd7NfxmA7JQHuXb9B-vQWkkRnd1yAx0LLRNCIzVP79~VTv9yiSj617GadMG5N~Wsa5WG0UzeW1Y2YA~lIu42en~3E55TX2ytaEgR-qQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

[View Original](https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/lieberman9781496324818-ch031_f022_1602178826.741.jpeg?Expires=1652066471&Signature=dGiqyoyPwv4MhAHWn5ys-tkOLCGCOurmWG~oGBIE5tK8Vv~jJi5D-xMlQmtO8u2rdoK-b0G7~LTWlZmQJXA-Uz0pV6laWqnq2LgFK9eeqDClsiLo1aR0nm6gV53JVlkNqoBDITGejYKPVdP-jeYGXQYBVyw4Gn-JQf83cfGk4x6I3syc9rTQrQ2Sjq~0jGNZwcccPjC2n6O8cXTlB8pFU4cQQhmL0f5WHMbzaBG3OL~RYZ8rJpFYBPoWMqNJLcAbYZzC1mpLuArG7-X4N3hTuB~gZYJdmMRQRpR81-Rco0n1hX-zuVeClR1OV9~8oaDqka1ODHFS4G0VoXo24wPCTA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)[Download Slide (.ppt)](https://meded-lwwhealthlibrary-com.eproxy.lib.hku.hk/downloadimage.aspx?sec=249267821&image=https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/lieberman9781496324818-ch031_f022_1602178826.741.jpeg?Expires=1652066471&Signature=dGiqyoyPwv4MhAHWn5ys-tkOLCGCOurmWG~oGBIE5tK8Vv~jJi5D-xMlQmtO8u2rdoK-b0G7~LTWlZmQJXA-Uz0pV6laWqnq2LgFK9eeqDClsiLo1aR0nm6gV53JVlkNqoBDITGejYKPVdP-jeYGXQYBVyw4Gn-JQf83cfGk4x6I3syc9rTQrQ2Sjq~0jGNZwcccPjC2n6O8cXTlB8pFU4cQQhmL0f5WHMbzaBG3OL~RYZ8rJpFYBPoWMqNJLcAbYZzC1mpLuArG7-X4N3hTuB~gZYJdmMRQRpR81-Rco0n1hX-zuVeClR1OV9~8oaDqka1ODHFS4G0VoXo24wPCTA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&ChapterSecID=249267688&BookID=2170)

**Synthesis of very-low-density lipoprotein (VLDL) from glucose in the liver.**

*G-6-P*, glucose 6-phosphate; *F-6-P*, fructose 6-phosphate; *F-1,6-BP*, fructose 1,6-bisphosphate; *FA*, fatty acyl group; *TG*, triacylglycerol; *DHAP*, dihydroxyacetone phosphate; *NAD*, nicotinamide adenine dinucleotide; *OAA*, oxaloacetate; *NADP*, nicotinamide adenine dinucleotide phosphate.

**FIGURE 31.23**

![https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/m_lieberman9781496324818-ch031_f023_1602178826.741.jpeg?Expires=1652066471&Signature=cIGJK2~CkLABu9tE41NXc2bDYn858U5AiMj5tnCbuBCESsIYapYU8ZOWrMZGCr0zmlyCfoIFw-gv-wGWNTDLO9YIGsci4Ji8VryKyYNgM6f531Ko461hC~a~ocDSwu1a4wxIhQ17U5yRBVF1iMqK2jT7QWg1f10~J~C1czWkzSZmsMX5h~mSyZ8vwt7TGlXgXCZkH2tEfiG5isG404lABkg4m-MjpxxY3RZDcQn7YmPWF64mM1Z9909NWQEjRoHfk2oCV8D7IZo5OqlwiM86QqIE00VdDhLQ3bV1mqU8sO9ZMBefAr-u3BOgsBsR-iTCsFAMZOjlP-xBjXpDg6ZZ2g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA](https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/m_lieberman9781496324818-ch031_f023_1602178826.741.jpeg?Expires=1652066471&Signature=cIGJK2~CkLABu9tE41NXc2bDYn858U5AiMj5tnCbuBCESsIYapYU8ZOWrMZGCr0zmlyCfoIFw-gv-wGWNTDLO9YIGsci4Ji8VryKyYNgM6f531Ko461hC~a~ocDSwu1a4wxIhQ17U5yRBVF1iMqK2jT7QWg1f10~J~C1czWkzSZmsMX5h~mSyZ8vwt7TGlXgXCZkH2tEfiG5isG404lABkg4m-MjpxxY3RZDcQn7YmPWF64mM1Z9909NWQEjRoHfk2oCV8D7IZo5OqlwiM86QqIE00VdDhLQ3bV1mqU8sO9ZMBefAr-u3BOgsBsR-iTCsFAMZOjlP-xBjXpDg6ZZ2g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

[View Original](https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/lieberman9781496324818-ch031_f023_1602178826.741.jpeg?Expires=1652066471&Signature=gzLKaG-h2y2FNCVWEi64DyjJk6c0Z1nX5mDcKYLC~KrfugU5ishUAa8~rmqKjJ9a7NVWnphKiyD5SP8~aUZSwoekRkYAcgXcREtcv6zUigiFOdUukATE1c7wvIX57g17CFgikTehMXkIjETOPpckqrXUGU7vhD0JO05qfQf8b6E4pcWWyJJljDvls0aFr6qcBEmooML2DpAn2Iut1pAd3lnD6gyBTD9ijxrSG-kpv-jojiU6mjeGazEbb~kjd0XIPabRT1v7UZlG5MWSb0CiuEO5zNpkXOamcH2zDSLQZiyuAk99p8RcO8uesX~Yhw6SuwNbjvSXENl~wS5DF5Tv0g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)[Download Slide (.ppt)](https://meded-lwwhealthlibrary-com.eproxy.lib.hku.hk/downloadimage.aspx?sec=249267822&image=https://hl.silverchair-cdn.com/wk/hl/content_public/book/2170/lieberman9781496324818-ch031_f023_1602178826.741.jpeg?Expires=1652066471&Signature=gzLKaG-h2y2FNCVWEi64DyjJk6c0Z1nX5mDcKYLC~KrfugU5ishUAa8~rmqKjJ9a7NVWnphKiyD5SP8~aUZSwoekRkYAcgXcREtcv6zUigiFOdUukATE1c7wvIX57g17CFgikTehMXkIjETOPpckqrXUGU7vhD0JO05qfQf8b6E4pcWWyJJljDvls0aFr6qcBEmooML2DpAn2Iut1pAd3lnD6gyBTD9ijxrSG-kpv-jojiU6mjeGazEbb~kjd0XIPabRT1v7UZlG5MWSb0CiuEO5zNpkXOamcH2zDSLQZiyuAk99p8RcO8uesX~Yhw6SuwNbjvSXENl~wS5DF5Tv0g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&ChapterSecID=249267688&BookID=2170)

**Synthesis, processing, and secretion of very-low-density lipoprotein (VLDL).**

Proteins synthesized on the rough endoplasmic reticulum (RER) (*circle 1*) are packaged with triacylglycerols in the endoplasmic reticulum and Golgi complex to form VLDL (*circle 2*). VLDL are transported to the cell membrane in secretory vesicles (*circle 3*) and secreted by exocytosis. *Red circles* represent VLDL particles. An enlarged VLDL particle is depicted at the bottom of the figure.

**Why do some people with alcoholism have high VLDL levels?**

****How Do You Respond?****

In alcoholism, NADH levels in the liver are elevated (see [Chapter 28](https://meded-lwwhealthlibrary-com.eproxy.lib.hku.hk/content.aspx?legacySectionId=lieberman5-lieberman-5-lieberman-ch028)). High levels of NADH inhibit the oxidation of fatty acids. Therefore, fatty acids, mobilized from adipose tissue, are re-esterified to glycerol 3-P in the liver, forming triacylglycerols, which are packaged into VLDL and secreted into the blood. Elevated VLDL is frequently associated with chronic alcoholism. As alcohol-induced liver disease progresses, the ability to secrete the triacylglycerols is diminished, resulting in a fatty liver.

## **Fate of the VLDL Triglyceride**

LPL, which is attached to the basement membrane proteoglycans of capillary endothelial cells, cleaves the triacylglycerols in both VLDL and chylomicrons, forming fatty acids and glycerol. Apolipoprotein CII, which these lipoproteins obtain from HDL, activates LPL. The low *K*m of the muscle LPL isozyme permits muscle to use the fatty acids of chylomicrons and VLDL as a source of fuel even when the blood concentration of these lipoproteins is very low. The LPL isozyme in adipose tissue has a high *K*m and is most active after a meal, when blood levels of chylomicrons and VLDL are elevated. The fate of the VLDL particle after triglyceride has been removed by LPL is the generation of an intermediate-density lipoprotein (IDL) particle, which can further lose triglyceride to become an LDL particle. The fate of the IDL and LDL particles is discussed in [Chapter 32](https://meded-lwwhealthlibrary-com.eproxy.lib.hku.hk/content.aspx?legacySectionId=lieberman5-lieberman-5-lieberman-ch032).